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Node-Negative Non-small Cell Lung Cancer
Pathological Staging and Survival in 1765 Consecutive Cases
Benjamin M. Robinson, BSc, MBBS, Catherine Kennedy, RMRA, Jocelyn McLean, RN, MN,
and Brian C. McCaughan, MBBS, FRACS
Introduction: This study aimed to evaluate prognostic factors in
patients with node-negative non-small cell lung cancer and to assess
revised International Association for the Study of Lung Cancer
staging recommendations for this group.
Methods: A retrospective analysis of 1765 consecutive pathologically
node-negative patients treated by surgical resection between 1984 and
2007 was performed. Survival analysis was conducted using the Ka-
plan-Meier method. The independence of prognostic factors was ana-
lyzed using multivariate Cox proportional hazards modeling.
Results: The median age of patients was 68 years, and the average
length of follow-up was 6.3 years. Perioperative mortality was 1.7%.
The median survival was 6.5 years, with a 56% of the cohort
surviving 5 years. Factors associated with poorer prognosis were
male gender (hazard ratio [HR]: 1.30, p  0.001), age (HR: 1.04
per year of increase, p  0.001), limited resection (HR: 1.30, p 
0.002) tumor size (HR: 1.10 per 10 mm increase, p  0.001), large
cell histopathological cell type (HR: 1.35, p  0.001), and positive
resection margins (HR: 1.58, p  0.002). T stage was a superior
predictor of survival than tumor size (p  0.001). There was no
difference in survival by T-stage descriptor within stage T2 or T3.
Conclusions: In surgically treated, node-negative non-small cell
lung cancer, revised International Association for the Study of Lung
Cancer staging criteria stratify survival well. Age, gender, and extent
of resection are also important predictors of survival. Current T-
stage descriptor groupings are appropriate.
Key Words: Non-small cell lung cancer, Staging, Survival,
Prognosis.
(J Thorac Oncol. 2011;6: 1691–1696)
Lung cancer is the fourth most common cause of cancer inAustralia and is the leading cause of cancer mortality and
disease burden. Age standardized incidence rates are 46.3 and
24.0 per 100,000 population for men and women, respec-
tively.1 Although lung cancer rates for men have been in
decline since the 1980s, incidence for women continues to
increase, reflecting patterns of disease distribution seen in
other developed countries.2
Non-small cell lung cancer (NSCLC) accounts for ap-
proximately 80% all lung cancer cases. The majority of
patients (70%) present with advanced disease that is not
amenable to surgery. The remainder present with early stage
and often asymptomatic malignancy. For this group of pa-
tients, surgical resection affords the most consistent curative
results. All such patients should, therefore, be considered for
surgical resection. Selection for surgery is based on the
histopathological confirmation of NSCLC, staging, and eval-
uation of patient fitness.
Accurate and reproducible staging is crucial to the
management of primary lung cancer and the assessment of
treatment. The International Association for the Study of
Lung Cancer (IASLC) has recently published an extensive
revision of tumor, node, and metastasis descriptors and stage
groupings that have been adopted by the Union Internationale
Contre le Cancer and the American Joint Committee on
Cancer (AJCC) staging systems.3
This study reviews survival, perioperative mortality,
and prognostic factors in a large cohort of pathologically
node-negative NSCLC cases. The outcomes are evaluated in
relationship to the standard variables of age, sex, extent of
resection, and histopathological cell type. We have also
updated all pathological staging to comply with the recent
IASLC revision and assess survival with respect to the
redefined tumor (T) stages. Finally, we examine the effect of
tumor descriptors on survival within stages.
PATIENTS AND METHODS
We performed a retrospective review of consecutive,
node-negative NSCLC cases, treated by surgical resection in
the Baird Institute Lung Cancer Database, from January 1984
to December 2007. All patients undergoing surgery for chest
malignancy at Royal Prince Alfred Hospital, Concord Repa-
triation General Hospital, and Strathfield Private Hospital are
added to this database prospectively.
Patients were originally staged according to the AJCC,
Cancer Staging Manual current at the time of resection.
Before this review, staging in all cases had been updated to
reflect the 6th Edition (AJCC-6).4,5 A single investigator
(CK) used operative and histopathological reports to restage
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all tumors included in this study according to the 7th edition
(AJCC-7).3
Node-negative cases were defined as those cases with
no histopathologically identified regional lymph node metas-
tases, i.e., nodal stage pN0.
The extent of resection was determined by the location
and size of the tumor, and the patient’s cardiorespiratory
reserve. A limited resection was performed when patient
fitness precluded an anatomical resection as a therapeutic
option. The extent of lymph node dissection was at the
discretion of the operating surgeon. The majority of patients
received a nodal sampling, from interlobar, peribronchial,
hilar, subcarinal, and ipsilateral paratracheal nodes.
After postoperative review at 6 weeks, patients were
followed up by the thoracic surgeon at 6-month intervals for
the first 2 years and yearly thereafter. Follow-up data were
also obtained from incoming correspondence, direct patient
contact, and by communication with the patient’s general
practitioner.
In the analysis of prognostic factors, age was evaluated
as both a continuous and binary variable with a 70-year
cutoff. Maximum tumor diameter was modeled as both a
continuous and discrete ordinal variable. Bronchioloalveolar
(BAC) carcinoma was included in the adenocarcinoma clas-
sification. Mixed tumors were included in the survival anal-
ysis. Carcinoid tumors are not included. We have previously
reported our experience with carcinoids over a similar pe-
riod.6 Incomplete resections are reported and subsequently
excluded from further analysis, so that valid comparisons
may be made with the IASLC registry, from which T-stage
recommendations were based on analysis of complete resec-
tions.7 Patients who had received neoadjuvant chemotherapy
and were subsequently classified as pN0 were excluded from
the study.
Extent of resection was analyzed as a binary nominal
variable, pneumonectomy, bilobectomy, and lobectomy were
considered anatomical. Wedge resection and segmentectomy
were grouped as limited resections. T2 and T3 stage T-de-
scriptor subgroups are as per the AJCC-7 classification.3
Tumors may be classified as T2 or T3 due to size, invasion
into surrounding tissues, or central bronchial involvement
and in the case of T3, due to separate tumor nodules in the
same lobe. We have labeled the latter, “Satellite.” The size T
descriptor “Size” is defined by a tumor of more than 3 cm but
7 cm for T2 and more than 7 cm for T3. The descriptor
“Central” for T2 tumors indicates involvement of a main
bronchus 2 cm distal to the carina or associated with
atelectasis or obstructive pneumonitis that extends to the
mediastinum but does not involve the entire lung. In T3
tumors, “Central” describes tumors of a main bronchus less
than 2 cm distal to the carina or associated with atelectasis or
obstructive pneumonitis of the entire lung. “Invasive” for T2
tumors describes visceral pleural invasion, whereas “Inva-
sive” in T3 tumors implies invasion of the parietal pleura,
chest wall, diaphragm, phrenic nerve, mediastinal pleura, or
parietal pericardium. When a tumor is ascribed more than one
of the above descriptors, it was classified in the “Multiple”
subgroup of its T stage. For example, a 5-cm tumor invading
visceral pleura qualifies for T2 due to size and invasion was
classified as “Multiple T2.”
Perioperative mortality was defined as death within 30
days of surgery and included in overall survival analysis.
Survival was calculated using the Kaplan-Meier method.8
Patients still alive at the time of the study were censored at
the last confirmed date of survival. The equality of survival
functions was assessed by the log-rank test. Observed all-
cause survival was used. The Cox proportional hazards model
was used to perform single and multivariable analysis of
prognostic factors. Models were compared by the likelihood
ratio test. Results were considered significant at p less than
0.05. All analyses were conducted using Stata version 11
(Stata Corporation, College Station, TX).
RESULTS
There were 2974 patients with NSCLC treated by
surgical resection in the defined period at participating insti-
tutions. Of these, 1765 (59%) had node-negative disease after
pathological staging and were included in this study. Patient
characteristics are listed in Table 1. The median age of
patients was 68 years (30–90) and comprised 70% males.
The majority of the cohort had anatomical resections (85%)
of predominantly adenocarcinoma or squamous cell histopa-
thology. There were no node-negative T4 tumors in the
cohort. The average period of follow-up was 6.3 years. A
total of 1200 (68%) patients died during follow-up, 677
(38%) from NSCLC recurrence. There were 30 perioperative
deaths, accounting for 1.7% of the cohort. Six deaths oc-
curred in pneumonectomy patients (3.1%), three in patients
undergoing limited resections (1.1%) and the remainder (21)
in the lobectomy and bilobectomy group (1.6%). Right-sided
procedures accounted for a significantly greater proportion
(77%) of perioperative mortality (p  0.03).
There were 80 (5%) extended resections in the cohort.
The majority of these involved en block resection of parietal
pleura (13) and chest wall (52). Sleeve resection of main stem
bronchus (7), resection of pericardium (7), or diaphragm (2)
accounted for the remainder.
Resection was complete (R0) in 96% of cases. Of the
67 cases with pathologically positive resection margins, the
majority (39) were stage T3. Median survival for these
patients was poor at 2.1 years (95% confidence interval [CI],
1.39–3.12). The hazard ratio (HR) for incomplete resection
adjusted for age, sex, cell type, T stage, and extent of
resection was 1.58 (95% CI, 1.2–2.1). These cases are in-
cluded in the descriptive statistics for the cohort (Table 1) but
excluded for subsequent analysis of survival, staging, and
prognostic factors.
Median and 5-year overall survival for node-negative,
completely resected NSCLC is listed in Table 2. The median
overall survival for all node-negative NSCLC was 6.5 years,
with a 5-year survival rate of 56%. Survival curves by
pathological cell type and tumor stage are illustrated in
Figures 1 and 2, respectively. In both cases, significantly
there were differences in survival distributions (log rank, p 
0.001). Given the recent subclassification of T1 and T2, we
repeated our survival analysis restricted to T1 and then
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again restricted to T2. In both these cases, the survival
differences T1a versus T1b (p  0.18) and T2a versus T2b
(p  0.07) were not significant. There was similarly no
survival difference for BAC within the adenocarcinoma
classification (p  0.38).
Table 3 lists HRs derived by application of Cox pro-
portional hazards models. Poor prognostic factors in the
multivariable regression were increasing age, tumor size,
male sex, and limited resection. Large cell carcinomas had
significantly poorer survival than both adenocarcinoma (HR:
1.43) and squamous cell types (HR: 1.30, 95% CI, 1.11–
1.56). Maximum tumor diameter displayed a linear relation-
ship with survival. After controlling for sex, histological cell
type, extent of resection, and age, HRs increased with in-
creasing T stage. In multivariate analysis, AJCC-7 tumor
stage classifications modeled survival significantly better than
tumor size alone, when models were compared by likelihood
ratio test (p  0.0004).
Survival curves within T stages 2 and 3, by T-stage
descriptors are illustrated in Figure 3. The distribution of
descriptors within stage groups is summarized in Table 1.
Tumor size was the predominant characteristic defining T2
classification (71%), whereas invasive malignancy indepen-
dent of tumor dimension accounted for the largest proportion
of the T3 group. There was no significant difference in
TABLE 1. Patient and Tumor Characteristics of 1765
Consecutive Node-Negative (pN0) NSCLC Cases
Variables No. of Patients Percentage
Age
Mean 66.9
Range 30–87
Sex
Male 1242 70
Female 523 30
Operation
Pneumonectomy 191 11
Lobectomy 1304 74
Limited resection 270 15
Side
Left 755 42
Right 1010 58
Cell type
Adenocarcinoma 735 42
Squamous cell 694 39
Large cell 276 16
Mixed cell types 60 3
T stage (AJCC 7)
T1a 289 16
T1b 356 20
T2a 527 30
T2b 345 20
T3 248 14
T2 descriptors
Size 626 72
Central 29 3
Invasive 138 16
Multiple T2 79 9
T3 descriptors
Size 75 30
Central 9 4
Invasive 96 39
Satellite 41 17
Multiple T3 27 11
NSCLC, non-small cell lung cancer; AJCC, American Joint Committee on Cancer.
TABLE 2. Median and 5-yr Survival by Prognostic Factor in
1698 Completely Resected Node-Negative NSCLC Cases
Variables Median (95% CI) 5 yr (95% CI)
All patients 6.5 (6.0–7.0) 56% (54–59)
Age
70 yr 8.1 (7.3–9.0) 62% (59–65)
70 yr 4.8 (4.4–5.5) 49% (45–53)
Gender
Male 5.7 (5.1–6.4) 53% (50–56)
Female 8.2 (7.2–9.6) 64% (60–68)
Extent of resection
Limited 4.7 (4.0–5.8) 49% (43–55)
Anatomical 6.9 (6.3–7.5) 58% (55–60)
Cell type
Adenocarcinoma 7.1 (6.1–7.7) 59% (56–63)
Squamous cell 6.4 (5.6–7.2) 56% (52–60)
Large cell 5.1 (3.5–6.8) 51% (45–57)
Mixed cell type 4.1 (2.2–8.0) 47% (34–59)
T stage (AJCC 7)
T1a 9.1 (7.0–10.0) 69% (63–74)
T1b 7.5 (6.7–9.0) 66% (61–71)
T2a 5.4 (4.6–6.7) 51% (47–56)
T2b 6.1 (4.6–7.5) 54% (49–59)
T3 3.2 (2.5–4.1) 39% (32–46)
NSCLC, non-small cell lung cancer; AJCC, American Joint Committee on Cancer;
CI, confidence interval.
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FIGURE 1. Kaplan-Meier survival curves for node-negative
non-small cell lung cancer (NSCLC) by cell type (log rank
p  0.001).
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survival within T2 or T3 by T descriptor on log-rank test.
Nevertheless, when T-stage descriptors were entered into a
Cox proportional hazards model as nominal categorical vari-
ables, controlling for age, sex, extent of resection, and histo-
logical cell type, multiple T3 descriptors were associated with
worse survival within that group (HR: 1.81, 95% CI: 1.01–
3.27).
DISCUSSION
In this study, we present a large cohort of pathologi-
cally node-negative, surgically treated NSCLC cases, staged
according to the revised Union Internationale Contre le Can-
cer/AJCC staging criteria. Our average follow-up of 6.3
years, 56% 5-year survival and low perioperative mortality
compare favorably to similar investigations examining early-
stage disease.9–12
For N0 NSCLC, the effect of AJCC-7 staging revisions
relates mainly to tumor size. The changes13 are as follows:
a. Subclassify T1 into T1a and T1b above and below a
maximum tumor diameter of 2 cm.
b. Similarly, subclassify T2 into T2a and T2b at 5 cm.
c. Reclassify tumors greater than 7 cm from T2 to T3.
d. Reclassify tumors with separate tumor nodules in the
same lobe from T4 to T3.
e. Reclassify tumors with malignant pleural effusion from
T4 to M1a.
f. Reclassify tumors with additional tumor nodules in
another ipsilateral lobe or lobes from M1 to T4.
The resulting tumor classification stratified survival
well in the present series. HRs increased with increasing T
stage. With respect to tumor size alone, however, we were
unable to demonstrate significant survival differences for the
new T1 and T2 subclassifications. Our study may be under-
powered to detect these differences. The recommendation for
a 2 cm size cutoff was made after the analysis of 2751 pT1
N0 R0 cases (learning and validation sets combined),
whereas the T2 distinction was based on 3647 pT2 N0 R0
cases.7 Before the new staging system, multiple studies had
argued for the greater stratification of small9,10,14 and large
tumors15,16 based on survival differences.
T stages are defined by tumor size and a collection of
tumor descriptors independent of size. We compared two
0.00
0.20
0.40
0.60
0.80
1.00
Pr
op
or
tio
n 
su
rv
ivi
ng
1 2 3 4 5 6 7 8 9 10
Years after surgery
T1a
T1b
T2a
T2b
T3
FIGURE 2. Kaplan-Meier survival curves for node-negative
non-small cell lung cancer (NSCLC) by American Joint Com-
mittee on Cancer (AJCC)-7 T stage (log rank p  0.0001).
TABLE 3. Univariate and Multivariate Hazard Ratios for Prognostic Factors in Completely
Resected, Node-Negative NSCLC
Variables Univariate (95% CI) p Multivariate (95% CI) p
Age
Per year 1.04 (1.04–1.05) 0.001 1.04 (1.03–1.05) 0.001
70 yr 1.64 (1.46–1.85) 0.001 1.63 (1.44–1.83) 0.001
Female 0.73 (0.63–0.82) 0.001 0.75 (0.68–0.85) 0.001
Limited resection only 1.23 (1.06–1.45) 0.008 1.30 (1.10–1.53) 0.002
Tumor size
Per 10 mm increase 1.10 (1.06–1.13) 0.001 1.11 (1.07–1.15) 0.001
Per doubling 1.25 (1.16–1.35) 0.001 1.28 (1.18–1.40) 0.001
Cell type
Adenocarcinoma Baseline Baseline
Squamous cell 1.16 (1.02–1.33) 0.022 1.04 (0.91–1.19) 0.56
Large cell 1.39 (1.17–1.64) 0.001 1.35 (1.13–1.60) 0.001
Mixed cell type 1.35 (0.97–1.89) 0.078 1.28 (0.92–1.80) 0.14
T stage (AJCC 7)
T1a Baseline Baseline
T1b 1.14 (0.93–1.40) 0.25 1.14 (0.93–1.39) 0.14
T2a 1.46 (1.21–1.75) 0.001 1.38 (1.16–1.65) 0.001
T2b 1.40 (1.15–1.71) 0.001 1.46 (1.20–1.77) 0.001
T3 2.00 (1.60–2.48) 0.001 2.15 (1.72–2.69) 0.001
NSCLC, non-small cell lung cancer; AJCC, American Joint Committee on Cancer; CI, confidence interval.
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multivariate survival models in our node-negative cohort.
The first model contained age, sex, extent of resection, cell
type, and T stage. The second model included the same
variables but substituted T stage for tumor size. The model
using T stages was a significantly better predictor of survival,
demonstrating the utility of nonsize-based tumor descriptors
in NSCLC prognosis and staging. Furthermore, we have
demonstrated an equality of survival functions for the various
T-stage descriptors within T2 and T3. The examination of
T-stage descriptors in a cohort restricted to N0 cases effec-
tively controls confounding by nodal disease. Our results,
therefore, support the suitability of current T-stage descriptor
groupings.
Our finding of poorer survival in patients undergoing
limited resection is confounded by the treatment policy at
participating institutions, whereby treatment choice is dic-
tated by performance status. Ginsberg and Rubinstein18 pre-
sented more compelling evidence for anatomical resection
from a randomized trial in early stage disease. They demon-
strated increased local recurrence and mortality (borderline)
after lesser resection. A number of studies nevertheless argue
for the equivalence of lesser resection for small peripheral
tumors particularly from Japan.18–20 These are not random-
ized and are often biased by a smaller average tumor size in
patients undergoing lesser resections. As such, our treatment
policy continues to favor anatomical resection in patients
with adequate cardiopulmonary reserve.
Male gender and advancing age have previously been
identified as poor prognostic factors after NSCLC resec-
tion.21,22 In this series, men had a 1.30 times greater risk of
mortality after resection of node-negative disease. Although a
proportion of this difference is due to the shorter life expec-
tancy of men and higher burden of cardiovascular comorbidi-
ties, there may be other gender-associated factors contribut-
ing to this result. The significance of age in all-cause survival
analysis is difficult to assess, as separating noncancer causes
of death is problematic. Despite the finding of a HR of 1.63
for patients older than 70 years, it is our opinion that age
alone should not preclude consideration for curative resec-
tion. Clinical staging and assessment of fitness remain the
primary determinants of treatment approach in this group.
Unsurprisingly, patients older than 70 years comprised a
comparatively larger proportion of the lesser resection group
(p  0.006) in this series.
With respect to histopathological cell type, our findings
differ from recent analysis of surgical NSCLC cases from the
IASLC lung cancer staging project. Chansky et al.21 demon-
strated superior prognosis for BAC compared with other
histologies and for squamous cell tumors over adenocarci-
noma and large cell. Other reports assessing to the impact of
histopathology on prognosis have been inconsistent and tend
to focus on the two most common non-small cell histologies.
Our results demonstrating a 1.35 times greater mortality risk
for large cell tumors may represent a true regional variation.
Nevertheless, confounding due to differences in performance
status or other unmeasured variables across groups may also
explain the finding.
The literature describes a diversity of operative ap-
proaches to mediastinal lymphatics; however, a meta-analysis
by Wright et al.23 found that complete dissection was asso-
ciated with improved survival. The extent of mediastinal
lymph node resection in our patient population requires
further investigation. Inadequate nodal dissection may lead
to the inclusion of occult nodal disease in a pathologically
node-negative cohort. Furthermore, the clinical character-
ization of our node-negative patients may be enhanced by
the inclusion of other variables in future survival analyses.
Candidate variables for investigation include detailed tu-
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FIGURE 3. Kaplan-Meier survival
curves for node-negative subjects
within T stage, by T-stage descrip-
tors. A, T2 (log rank p  0.19). B,
T3 (log rank p  0.75).
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mor histopathology, the use of adjuvant therapies, and
patient genetics.
In the interim, this study confirms the usefulness of
AJCC-7 in stratifying survival after resection of node-nega-
tive NSCLC in a large, multicenter cohort. Age, gender, and
extent of resection are also important prognostic factors.
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